The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
The Oncology Institute, Inc.NASDAQ: TOI
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to -1.7%
Net margin was -1.7% in Q1 FY2026, up 17.1 pp from a year earlier. On a trailing-twelve-month basis it was -8.0%, up 8.0 pp year over year. Over 3 fiscal years it narrowed by 12.1 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 3 analysts of -21.2% for the fiscal year ending Dec 2026, down from -12.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1.7%+3.6 pp QoQ
- Last fiscal yearDec 2025
- -12.1%+4.4 pp YoY
- LTMMar 2026
- -8.0%+8.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.1 pp | -24.4 pp | -41.5 pp |
| 1 year | +4.4 pp | -9.1 pp | -13.5 pp |
| 3 years | -12.1 pp | +14.6 pp | +26.7 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -12.1%
- Year-over-year change
- +4.4pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -12.1% | +4.4pp |
| FY2024 | 2024-12-31 | -16.4% | +9.2pp |
| FY2023 | 2023-12-31 | -25.6% | -25.7pp |
| FY2022 | 2022-12-31 | 0.1% | +5.4pp |
| FY2021 | 2021-12-31 | -5.4% | — |
Net Margin vs competitors
How TOI compares with its peers on the latest reported figures
- TOI's LTM Mar 2026 net margin of -8.0% is the 3rd highest of the 10 companies compared; the peer median is -16.3%.
- Its year-over-year change of +8.0 pp is the 2nd highest of 10, against a peer median of -2.1 pp.
- Over three fiscal years its change of -12.1 pp compares with a peer median of +4.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | 1.5% | -2.1 pp | +5.7 pp |
| LTM Mar 2026 | -6.4% | -2.4 pp | -2.4 pp | |
| LTM Mar 2026 | -8.0% | +8.0 pp | -12.1 pp | |
| LTM Mar 2026 | -9.8% | -8.4 pp | -15.6 pp | |
| LTM Mar 2026 | -14.4% | +6.0 pp | +32.7 pp | |
| LTM Mar 2026 | -16.3% | +2.8 pp | -17.8 pp | |
| LTM Mar 2026 | -24.2% | -11.5 pp | +4.2 pp | |
| LTM Mar 2026 | -29.4% | -4.3 pp | +2.4 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -63.5% | -0.9 pp | +83.4 pp |
| LTM Mar 2026 | -312.0% | +2330.7 pp | +2021.6 pp | |
| Peer median (excluding TOI) | -16.3% | -2.1 pp | +4.2 pp | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 203M | 252.48M | 324.24M | 393.41M | 502.73M |
| Cost of Revenue | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M |
| Gross Profit | 40.85M | 52.09M | 59.57M | 54M | 76.44M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 15.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 105.57M |
| Operating Expenses | 86.71M | 134.04M | 136.59M | 114.12M | 112.52M |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| EBITDA | (42.04M) | (67.6M) | (54.28M) | (50.88M) | (42.52M) |
| EBITDA Margin | -20.7% | -26.8% | -16.7% | -12.9% | -8.5% |
| Operating Income | (45.86M) | (81.95M) | (77.02M) | (60.12M) | (36.08M) |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 320K | 4.08M | 6.78M | 7.5M | 11.28M |
| Other Income / Expenses | 34.26M | 81.86M | (6.09M) | (4.55M) | (24.65M) |
| Income Before Tax | (11.6M) | (91K) | (83.1M) | (64.66M) | (60.74M) |
| Pre-Tax Margin | -5.7% | -0.0% | -25.6% | -16.4% | -12.1% |
| Income Tax Expense | (671K) | (243K) | (36K) | 0 | (131K) |
| Net Income | (10.93M) | 152K | (83.07M) | (64.66M) | (60.61M) |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Basic) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) |
| EPS (Diluted) | (0.16) | (0.21) | (0.92) | (0.71) | (0.54) |
| Weighted Avg Shares | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M |
| Weighted Avg Shares (Diluted) | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.